ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1203

Analysis of the Impact of Tofacitinib Treatment on Weight in Patients with Rheumatoid Arthritis

Jürgen Wollenhaupt1, Jacques Morel2, Claire Daien3, Adeline Ruyssen-Witrand4, Cédric Lukas3, Christophe Richez5, Andrea Shapiro6, Douglass S Chapman7, Magali Cros8, Jose L Rivas9 and Gustavo Citera10, 1Struenseehaus Centre for Rheumatology and Clinical Immunology, Hamburg, Germany, 2Rheumatology department, CHU Montpellier and University of Montpellier, Montpellier, France, 3CHU Montpellier and University of Montpellier, Montpellier, France, 4Hôpital Purpan, CHU Toulouse, Toulouse, France, 5Groupe Hospitalier Pellegrin-CHU de Bordeaux, Bordeaux, France, 6Pfizer Inc, Peapack, NJ, 7Pfizer Inc, New York, NY, 8Pfizer Inc, Paris, France, 9Pfizer SLU, Madrid, Spain, 10Instituto de Rehabilitación Psicofísica, Buenos Aires, Argentina

Meeting: ACR Convergence 2020

Keywords: body mass, rheumatoid arthritis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 8, 2020

Title: RA – Treatments Poster III: PROs, Biomarkers, Systemic Inflammation & Radiographs

Session Type: Poster Session C

Session Time: 9:00AM-11:00AM

Background/Purpose: A prior post hoc analysis of tofacitinib clinical trial data reported improvements in RA outcomes with tofacitinib vs placebo (PBO) through Month (M)6, regardless of baseline (BL) BMI.1 This post hoc analysis assessed change from BL (∆) in BMI, and disease activity by BL BMI status, in patients (pts) with moderate/severe RA receiving tofacitinib through M12.

Methods: Data were pooled from Phase 3 and 3b/4 studies of pts who were MTX-naïve (NCT01039688), or inadequate responders to conventional synthetic (cs) or biologic DMARDs (NCT00960440; NCT00847613; NCT00814307; NCT00856544; NCT00853385; NCT02187055; NCT02831855). Pts received ≥ 1 dose of tofacitinib 5 or 10 mg twice daily (BID), or 11 mg once daily (QD), alone or with background csDMARDs, or PBO. Least squares (LS) mean ∆BMI (linear mixed model repeated measures; observed cases) was summarized for all treatment groups at M3/6/12 (M3/6 only for tofacitinib 11 mg QD and PBO). Other assessments at M3/6/12 included ∆BMI +/‑ BL concomitant glucocorticoids (GC) or antidepressants (descriptive statistics only), LS mean ∆DAS28‑4(ESR), stratified by BL BMI status (< 25, ≥ 25 – < 30, ≥ 30), and correlations between LS mean ∆BMI and ∆DAS28‑4(ESR).

Results: In total, 2,349, 1,611, 694, and 681 pts received tofacitinib 5 mg BID, 10 mg BID, 11 mg QD, or PBO, respectively. Demographics and baseline characteristics were generally similar across treatment groups, except in pts receiving tofacitinib 11 mg QD, where some differences were observed in gender, race, and concomitant GC use (Table 1). At M3/6, LS mean BMI significantly increased from BL with all tofacitinib doses vs PBO (all p< 0.05); ∆BMI was greatest with 10 mg BID, and lowest with 11 mg QD (Figure 1a). LS mean ∆BMI was greater in pts receiving tofacitinib as monotherapy vs combination therapy at M3/6/12 (Figure 1b). ∆BMI was generally similar in pts receiving treatment +/‑ concomitant GCs or antidepressants (data not shown). Improvements in DAS28‑4(ESR) scores were observed in each BL BMI status group at M3/6/12, and were greatest with all tofacitinib doses vs PBO. LS mean ∆DAS28‑4(ESR) was generally numerically highest for pts with BMI < 25 and numerically lowest for pts with BMI > 30, for all tofacitinib doses. LS mean ∆DAS28‑4(ESR) was also generally greatest with tofacitinib 10 mg BID and 11 mg QD vs 5 mg BID across BL BMI status groups (Figure 1c). Across treatment groups, model-adjusted associations between ∆DAS28-4(ESR) scores and ∆BMI were weak (correlation coefficients all < 0.3; Table 2).

Conclusion: ∆BMI was greater with tofacitinib (all doses) vs PBO at M3/6, and with tofacitinib monotherapy vs combination therapy at M3/6/12. Improvements in DAS28‑4(ESR) were seen across all BL BMI status groups. BMI increases with tofacitinib were only weakly associated with DAS28-4(ESR) improvements. The relationship between disease activity and ∆BMI requires further investigation.

  1. Dikranian A et al. Arthritis Rheumatol 2018; 69 (suppl 10).

Acknowledgments: Study sponsored by Pfizer Inc. Medical writing support was provided by Anthony G. McCluskey, CMC Connect, and funded by Pfizer Inc.


Disclosure: J. Wollenhaupt, Pfizer Inc, 5, 8; J. Morel, AbbVie, 5, Bristol-Myers Squibb, 2, 5, Eli Lilly, 5, Novartis, 5, Pfizer Inc, 2, 5, Sanofi, 5; C. Daien, AbbVie, 2, Abivax, 5, Bristol-Myers Squibb, 2, Eli Lilly, 2, MSD, 2, Novartis, 2, Pfizer Inc, 2, Roche-Chugaï, 2, Sandoz, 2; A. Ruyssen-Witrand, None; C. Lukas, None; C. Richez, None; A. Shapiro, Pfizer Inc, 1, 3; D. Chapman, Pfizer Inc, 1, 3; M. Cros, Pfizer Inc, 1, 3; J. Rivas, Pfizer Inc, 1, 3; G. Citera, AbbVie, 5, 8, Eli Lilly, 5, 8, Bristol-Myers Squibb Company, 5, 8, Gema, 5, 8, Pfizer, 5, 8, Janssen, 5, 8.

To cite this abstract in AMA style:

Wollenhaupt J, Morel J, Daien C, Ruyssen-Witrand A, Lukas C, Richez C, Shapiro A, Chapman D, Cros M, Rivas J, Citera G. Analysis of the Impact of Tofacitinib Treatment on Weight in Patients with Rheumatoid Arthritis [abstract]. Arthritis Rheumatol. 2020; 72 (suppl 10). https://acrabstracts.org/abstract/analysis-of-the-impact-of-tofacitinib-treatment-on-weight-in-patients-with-rheumatoid-arthritis/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2020

ACR Meeting Abstracts - https://acrabstracts.org/abstract/analysis-of-the-impact-of-tofacitinib-treatment-on-weight-in-patients-with-rheumatoid-arthritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology